Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
641-660 of 2,251 trials

Severe Corneal Ulcers: NANOULCOR Treatment

We are studying an artificial cornea model for patients with severe corneal ulcers that don't respond to regular treatments. The goal is to see if it helps heal the ulcers and improves vision.

Corneal Ulcer≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Metastatic Prostate Cancer: ProBio Study

We are investigating if treatment choices based on biomarker signatures can improve survival and quality of life for patients with metastatic prostate cancer. This study compares these personalized approaches to standard care.

Metastatic Prostate CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Staphylococcus Aureus Bacteraemia: Bensylpenicillin vs. Cloxacillin

We are comparing two antibiotics to see which one works better for patients with a specific bacterial infection. The study looks at treatment outcomes, relapse rates, and side effects.

Staphylococcus aureus Bacteraemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Chronic Hepatitis B: Long-Term Study on Treatment Response

We are investigating how well previous participants of a hepatitis B treatment maintain their health over time. This study focuses on those who have stopped certain therapies and aims to understand their long-term outcomes.

Chronic Hepatitis BEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInfectious Diseases

Late Renal Graft Failure: Immunosuppression Study

We are comparing the effects of continuing versus stopping immunosuppression in patients with late renal graft failure. This study aims to see how these approaches impact health outcomes over two years.

Kidney Transplant>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineNephrology

Rectal Adenocarcinoma: Contact X-Ray Brachytherapy Study

We are studying whether adding contact X-ray brachytherapy to standard treatment can help preserve the rectum and improve survival in patients with intermediate substage rectal adenocarcinoma. We will also assess its impact on quality of life and side effects.

Rectal Adenocarcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Alectinib Dosing: Standard vs. Personalized Approach

We are comparing standard alectinib dosing to a personalized dosing method based on blood levels for patients with specific alectinib concentrations. The goal is to see if personalized dosing improves treatment outcomes and safety.

ALK Positive Non-Small Cell Lung Cancer1-2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Follicular Lymphoma: Epcoritamab with Rituximab and Lenalidomide

We are studying a new treatment combination for adults with previously untreated follicular lymphoma. The goal is to see if it works better and has fewer side effects than standard chemotherapy.

Follicular LymphomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Oocyte Donation: Corifollitropin alfa vs. Daily rFSH

We are studying whether Corifollitropin alfa can help increase the number of eggs collected from oocyte donors compared to standard daily treatments. This trial involves women using hormone suppression to improve egg quality.

Female Infertility1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and Obstetrics

Cleft Palate Treatment: Tissue-Engineered Oral Mucosa Substitute

We are testing a new tissue-engineered substitute for patients with cleft palate to see if it is safe and effective for healing and improving quality of life. The study will compare outcomes with standard treatments.

Cleft Lip and Palate>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyOrthopedics and TraumatologyPediatrics

Stroke Treatment: Intra-Arterial Thrombolysis Study

We are studying whether adding a specific clot-dissolving treatment helps improve recovery in patients with acute strokes who have already had successful blood flow restoration. This trial will also evaluate safety and costs associated with this treatment.

Ischemic Stroke1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Placental Vascularization Study: Contrast Ultrasound

We are examining how contrast-enhanced ultrasound can help assess blood flow in the placenta for patients undergoing medical termination of pregnancy. This study compares cases of fetal growth restriction with those without to better understand placental health.

Fetal Growth RestrictionConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Nerve Damage from Cancer: New Immunotherapy Approach

We are studying a combination of treatments for patients with anti-Hu-associated nerve damage due to cancer. The goal is to see if this early immunotherapy improves symptoms and helps patients live longer without cancer progression.

Paraneoplastic Neurological Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Coronary Artery Disease: SYN2 PET Scan Study

We are testing a new tracer for PET scans to see if it helps diagnose coronary artery disease in patients who may have it. The study will also assess the safety of this new diagnostic method.

Coronary Artery Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCardiology

Non-Hodgkin Lymphoma: IPH6501 Treatment Study

We are investigating a new drug, IPH6501, for patients with relapsed or refractory Non-Hodgkin Lymphoma. The study focuses on its safety and early signs of effectiveness in treating this type of cancer.

Refractory Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Influenza Vaccine Study for Adults Aged 65-79

We are comparing a high-dose flu vaccine to a standard-dose vaccine to see which one better reduces hospital visits for flu and pneumonia in older adults. This study aims to improve vaccine effectiveness for this age group.

Prevention of Influenza Infection in Older AdultsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Prostate Cancer: Pembrolizumab Combination Therapy

We are studying a new combination therapy with pembrolizumab for men with metastatic castration-resistant prostate cancer. The trial aims to evaluate its safety and how well it reduces PSA levels compared to standard treatments.

Metastatic Castration-Resistant Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Bomedemstat for Blood Disorders: Safety and Efficacy Study

We are studying the safety of bomedemstat for individuals with essential thrombocythemia, polycythemia vera, or myelofibrosis who participated in a previous study. The trial also examines how well the treatment manages these conditions over time.

Myeloproliferative Neoplasms>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Glioblastoma Treatment: Lomustine and Temozolomide Study

We are studying whether a combination of lomustine and temozolomide improves survival for newly diagnosed glioblastoma patients with a specific genetic marker. This trial also looks at side effects and quality of life compared to standard treatment.

Glioblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurologyOncology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology